Precision BioSciences

126 articles with Precision BioSciences

• Precision BioSciences Appoints Renowned Hematologist Alan List, M.D. as Chief Medical Officer

  4/15/2021

  Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced that Alan List, M.D. has been appointed as the Company’s Chief Medical Officer and a member of the senior leadership team at Precision BioSciences.

• Precision BioSciences Reacquires Global Rights to its Allogeneic CAR T Programs

  4/15/2021

  - Precision Reacquires from Servier its Global Development and Commercialization Rights and Control of All Partnered CAR T Programs, Including PBCAR0191 and PBCAR19B Stealth Cell - Servier Eligible to Receive Milestones and Royalties Based on Program Success

• Precision BioSciences Appoints Stanley R. Frankel, M.D. to Board of Directors

  4/12/2021

  Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS ® genome editing platform, today announced that Stanley R. Frankel, M.D. has been appointed as a Director on the Company’s Board of Directors and a member of the Board’s Science and Technology Committee

• Precision BioSciences to Participate in the Truist Securities 2021 Life Sciences Virtual Series

  4/9/2021

  Precision BioSciences Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced that Derek Jantz, Ph.D., Chief Scientific Officer and Co-Founder will participate in a fireside chat at the Truist Securities 2021 Life Sciences Virtual Series.

• Precision BioSciences Announces CEO Transition PlanBegins Search for Next Chief Executive Officer

  4/6/2021

  Precision BioSciences Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS ® genome editing platform, today announced a Chief Executive Officer transition plan and the initiation of a public search for a new CEO. Matt Kane, Co-Founder and Chief Executive Officer, is expected to continue in his current leadership capacity and as a board member

• Precision BioSciences to Participate in the Guggenheim Healthcare Talks 2021 Genomic Medicines & Rare Disease Day

  3/29/2021

  Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced it will participate in the Guggenheim Healthcare Talks 2021 Genomic Medicines & Rare Disease Day on April 1, 2021.

• Precision BioSciences Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides Business Update

  3/18/2021

  Established in vivo genome editing research collaboration and exclusive license agreement with Eli Lilly Reported interim data from Phase 1/2a study of PBCAR0191; updated interim data expected by mid-year 2021 Interim data releases expected from PBCAR269A and PBCAR20A in 2021 Received FDA acceptance of IND application for PBCAR19B, a next-generation, stealth cell, anti-CD19 allogeneic CAR T candidate for non-Hodgkin lymphoma;

• Precision BioSciences to Report Fourth Quarter and Fiscal Year 2020 Financial Results on March 18, 2021

  3/12/2021

  Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company, today announced it will publish fourth quarter and fiscal year 2020 financial results and provide a business update on Thursday, March 18, 2021.

• Precision BioSciences to Present at Upcoming Virtual Investor Conferences - Mar 02, 2021

  3/2/2021

  Precision BioSciences, Inc., a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, announced management will participate in the following upcoming virtual investor conferences:

• Precision Announces 3-Year Pre-clinical Study Results Showing Long-term Durability and Safety of ARCUS In Vivo Gene Editing to Cut LDL Cholesterol Levels in Nonhuman Primates

  2/19/2021

  Study Led by Gene Therapy Program at the University of Pennsylvania Published in Molecular Therapy

• 

  Precision’s Stealth Cell Allogeneic CAR T Candidate Engineered for Persistence

  2/11/2021

  Precision BioSciences recently received a notice of allowance for a new patent for PBCAR19B, its stealth cell, CD19 allogeneic CAR T candidate for non-Hodgkin lymphoma.

• Precision BioSciences to Present at Guggenheim Healthcare Talks 2021 Oncology Day

  2/4/2021

  Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage biotechnology company dedicated to improving life with its proprietary ARCUS ® genome editing platform, today announced it will participate in the Guggenheim Healthcare Talks 2021 Oncology Day on February 11, 2021 at 2:00 PM ET. A live webcast of the presentation will be accessible on the Company’s website, www.precisionbiosciences.com , in the Investors & Media section under Eve

• Precision BioSciences Receives Notice of Allowance for U.S. Patent Application Covering PBCAR19B, a Stealth Cell, CD19 Allogeneic CAR T Candidate for Non-Hodgkin Lymphoma

  1/25/2021

  Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage biotechnology company dedicated to improving life with its wholly proprietary ARCUS ® genome editing platform, today announced it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application covering PBCAR19B, a next-generation, stealth cell, CD19 product candidate for patients with relapsed/refractory (R/R) Non-Hodgkin Lymphoma (NHL). The allo

• Precision BioSciences Announces FDA Accepts IND for PBCAR19B, a Next-Generation, Stealth Cell, CD19 Allogeneic CAR T Candidate for Non-Hodgkin Lymphoma

  1/19/2021

  Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its wholly proprietary ARCUS® genome editing platform, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for PBCAR19B, a next-generation, stealth cell,

• Precision BioSciences to Present at the Annual J.P. Morgan Healthcare Conference

  1/4/2021

  Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform, today announced that Matt Kane, Co-founder and Chief Executive Officer and Derek Jantz, Ph.D., Co-Founder and Chief Scientific Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference

• Precision BioSciences Announces Executive Leadership Change

  12/14/2020

  Precision BioSciences, Inc. a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform, announced that Abid Ansari, Chief Financial Officer, notified the Company that he will be leaving the organization after nearly five years to pursue a new career opportunity.

• Precision BioSciences Reports Positive Interim Results from PBCAR0191 Phase 1/2a Trial in Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) and R/R B-cell Acute Lymphoblastic Leukemia (B-ALL)

  12/4/2020

  Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform, today announced positive interim clinical results from its Phase 1/2a study of PBCAR0191, the Company’s off-the-shelf allogeneic CAR T cell therapy investigational candidate targeting CD19.

• Precision BioSciences to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference

  11/24/2020

  Precision BioSciences, Inc., a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform, announced that its Chief Scientific Officer, Derek Jantz, Ph.D., will participate in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference, November 30 – December 3, 2020.

• Lilly and Precision BioSciences Announce Genome Editing Research Collaboration and License Agreement

  11/20/2020

  Eli Lilly and Company (NYSE: LLY) and Precision BioSciences, Inc. (Nasdaq: DTIL) today announced a research collaboration and exclusive license agreement to utilize Precision's proprietary ARCUS® genome editing platform for the research and development of potential in vivo therapies for genetic disorders, with an initial focus on Duchenne muscular dystrophy (DMD) and two other undisclosed gene targets.

• 

  Could Eli Lilly and Precision BioSciences Make Breakthroughs for DMD?

  11/20/2020

  Eli Lilly and Company and Precision BioSciences, Inc. announced today that they have entered a research collaboration and exclusive license agreement.